Drug intelligence / Profile preview

HRS-4139

Development stage: Phase 1
Lead developer: Fujian Shengdi Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

HRS-4139 is an oral small molecule therapeutic candidate being developed by Beijing Tuojie Biomedical Technology and Fujian Shengdi Pharmaceutical (a subsidiary of Jiangsu Hengrui Pharmaceuticals) for the treatment of psoriasis vulgaris. It is currently undergoing Phase I clinical evaluation in healthy participants to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics. The specific molecular target and mechanism of action of HRS-4139 have not been publicly disclosed.

Beyond the preview

Go deeper on HRS-4139.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HRS-4139.

Explore the full profile